OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Apple Turns 50: From Garage Startup to AI Crossroads 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Britain Courts Anthropic Amid US Defense Department Dispute 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
NEW YORK, Oct. 07, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Spectrum Pharmaceuticals, Inc. (“Spectrum Pharmaceuticals”) (NASDAQ:SPPI) between December 16, 2015 and September 16, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Nevada. If you purchased or otherwise acquired Spectrum Pharmaceuticals between December 16, 2015 and September 16, 2016, your rights may be affected by this action. To get more information go to:
http://www.zlk.com/pslra/spectrum-pharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the "FDA") questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants' public statements concerning the Company's business, operations and prospects were materially false and misleading at all relevant times.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
